Scope & Claims Analysis and US Patent Landscape for US 6,884,793 (Estradiol Valerate + Dienogest Contraception)
US Patent 6,884,793 is directed to a phasic, multi-stage oral contraception pack that uses estradiol valerate (EV) at two different EV dose levels across time stages, plus dienogest (DNG) in a two-group, higher DNG dosing segment, followed by EV-only and then placebo dosing. The claims are highly structural, pack-sequence specific, and dose-ratio specific, which narrows direct design-around space to alterations in (i) stage sequence, (ii) EV “high vs low” levels by stage, (iii) DNG ratio between first-group and second-group days, and (iv) group day counts.
What are the exact claim elements in US 6,884,793 for estradiol valerate plus dienogest contraception?
Claim 1: Two-stage EV dose levels, two DNG subgroups, and EV-only third stage
Claim 1 requires, in one “combination preparation,” all of the following:
-
First stage (2 daily dosage portions)
- Each day contains an “effective amount” of estradiol valerate.
- So there are 2 consecutive EV-only days at a first EV dose level.
-
Second stage (17 + 5 daily dosage portions; total 22 days) split into two groups
- The second stage has:
- First group: 5 daily dosage portions of a combination (EV + DNG)
- Second group: 17 daily dosage portions of a combination (EV + DNG)
- Within the second stage:
- “respective amounts of estradiol valerate in each daily dosage portion” in the second stage are equal (EV fixed across the entire second stage)
- “respective amounts of dienogest” in the second group are equal (DNG fixed within the second group)
- Critical ratio requirement:
- DNG in the second group is 1.5 to 3 times the DNG amount in the first group (and “corresponding amounts” ties the ratio between the two DNG groups).
-
Third stage (2 daily dosage portions) EV-only at a lower EV dose
- Each day contains an effective amount of EV only.
- EV in this third stage is:
- “the same, but smaller” than the EV amount in each first-stage daily portion.
- So EV takes a “high” level in stage 1 and a “lower” level in stage 3.
-
Additional stage (placebo)
- 2 daily dosage portions of a pharmaceutically acceptable placebo.
Total day-count implied by claim 1 structure:
- Stage 1: 2
- Stage 2: 22 (5 + 17)
- Stage 3: 2
- Placebo stage: 2
= 28-day regimen
Claim 2: EV numeric range + “minimum necessary” DNG in first-group
Claim 2 depends on claim 1 and narrows:
- EV in each first-stage daily portion: 3 to 4 mg/day
- DNG in each first-group day of the second stage:
- “minimum amounts necessary for effective contraceptive activity” (functional limitation rather than numeric, but it constrains the claim’s coverage to a minimum-efficacy dosing design)
Claim 3: Different pack balance (3 EV high days, 3 placebo days, 4 + 16 DNG split)
Claim 3 depends on claim 1 but changes multiple pack architecture parameters:
-
First stage: 3 daily EV-only portions (instead of 2)
-
Second stage: split as:
- First group: 4 daily portions of EV + DNG
- Second group: 16 daily portions of EV + DNG
- Same EV equality across the second stage (“each daily dosage portion” has equal EV)
- Same DNG equality within each subgroup
- Same DNG ratio requirement:
- DNG(second group) is 1.5 to 3 times DNG(first group)
-
Third stage: 2 daily EV-only portions with EV lower than stage 1
- The EV in third stage is “same, but smaller” than EV in each first-stage portion (same relational structure as claim 1).
-
Additional placebo stage: 3 placebo days (instead of 2)
Total day-count implied by claim 3 structure:
- Stage 1: 3
- Stage 2: 20 (4 + 16)
- Stage 3: 2
- Placebo: 3
= 28-day regimen (again)
Claim 4: EV numeric range + “minimum necessary” DNG again
- EV in each first-stage daily portion: 3 to 4 mg/day
- DNG in first group of second stage: “minimum amounts necessary for effective contraceptive activity.”
Claim 5: Fixed DNG unit (1 mg in each first-group day)
Claim 5 depends on claim 3 or 4 and adds:
- 1 mg dienogest present in each daily dosage portion in the first group of the second stage.
This makes DNG in the second group necessarily 1.5 to 3 mg per corresponding day (by the claim 3/1 ratio rule), assuming the “corresponding amounts” map 1:1 across the two groups.
How do the dosage timing and subgroup counts narrow infringement risk under US 6,884,793?
The claim is not simply “EV + DNG contraception.” It is a pack-program claim with explicit day counts and explicit stage boundaries. In practical freedom-to-operate terms, the infringement hooks are:
1) Stage boundary rigidity (sequence matters)
The claim defines a four-part sequence:
- EV-only high level (stage 1)
- EV + DNG with two DNG levels (stage 2 split into two groups)
- EV-only low level (stage 3)
- placebo (final stage)
A generic or competitor product that uses:
- a different ordering,
- a different number of EV-only days at the start,
- an EV + DNG overlap into placebo,
- or rebrands one segment without matching the claim’s “stage” definition
creates substantial design-around opportunity.
2) The “two EV dose levels” requirement
Both claim 1 and claim 3 require:
- EV in stage 3 is the same within stage 3 but smaller than EV in stage 1.
If an accused product uses:
- constant EV dosing across EV-only segments, or
- noncomparable EV quantities, or
- a monotonic change without the “same but smaller” pattern,
then it falls outside the claim’s relational limitation.
3) Second-stage subgroup day counts are explicit
- Claim 1: 5 first-group days + 17 second-group days
- Claim 3: 4 first-group days + 16 second-group days
A product with identical molecules and similar ratios but different day allocation is unlikely to match the claim’s element structure.
4) The DNG ratio is bounded (1.5x to 3x)
The second-stage DNG amounts must be in a bounded ratio:
- DNG(second group) = 1.5 to 3 times DNG(first group)
A ratio outside this window, even if close, avoids the literal “1.5 to 3 times” limitation.
5) Claim 2/4 and claim 5 add numeric constraints
- Claim 2/4: EV in stage 1 must be 3 to 4 mg/day
- Claim 5: DNG(first group) must be 1 mg per day, forcing DNG(second group) to land within 1.5 to 3 mg per day (subject to the same ratio and daily “corresponding amounts”).
These dependent claims are tighter and represent the best leverage for enforcement against close copies.
What is the likely independent claim coverage breadth based on the provided claim set?
Based only on claims 1–5 text supplied, the independent coverage is effectively the combination preparation defined by:
- EV + DNG only in stage 2
- EV-only in stages 1 and 3 with a fixed relational dose difference (stage 3 EV lower than stage 1 EV)
- fixed day counts for stage 1, stage 2 split groups, stage 3, and placebo
- fixed DNG ratio between second-stage subgroups (1.5x to 3x)
- fixed EV across the second stage (equal EV amount per day within stage 2)
This is narrower than broad “multiphase contraceptive regimens” and closer to product-specific pack architecture protection.
Which design-arounds are most plausible against US 6,884,793 based on claim limitations?
A. Change the stage lengths
- Alter the number of first-stage EV-only days (2 vs 3)
- Alter the placebo days (2 vs 3)
- Alter the second-stage day allocation (5/17 vs 4/16)
Any one of these can break literal infringement because the claims recite exact numbers of daily dosage portions in each group/stage.
B. Break the “EV lower in third stage” relationship
If an accused product uses EV-only segments at equal doses, it avoids the “smaller” EV relationship.
C. Move DNG outside the two-group structure
If DNG is varied gradually, uses more than two DNG levels, or uses a different subgroup arrangement, it can fall outside:
- “first group” vs “second group” with equal amounts in each group,
- and the requirement that ratio between groups is 1.5 to 3.
D. Push DNG ratio outside 1.5–3
If first-group DNG is adjusted so that second-group DNG is, for example, 1.4x or 3.2x, literal infringement is disrupted.
E. Target dependent-claim numeric carveouts
- If stage 1 EV is not 3–4 mg/day, claims 2 and 4 are avoided.
- If DNG(first group) is not 1 mg, claim 5 is avoided.
However, avoiding dependent claims does not necessarily avoid claim 1 or 3 unless those numeric constraints are also off-target.
How does this claim set compare with typical multiphase oral contraceptive patent patterns?
In many oral contraceptive regimens, patents claim either:
- molecule compositions (EV+DNG dosage amounts),
- broad ranges for dosing,
- or method-of-use contraceptive efficacy.
US 6,884,793’s supplied claim set is closer to formulation-in-use combined with regimen schedule protection:
- It uses explicit day counts and a structured multi-stage dosing program.
- It uses ratio constraints between subgroup days.
- It includes functional “minimum amounts necessary” language, signaling that some dosing is tied to efficacy without specifying a full numeric ceiling.
This architecture makes enforcement more dependent on the accused product’s exact pack design rather than only the total daily averages.
What is the US patent landscape for EV + dienogest contraceptive regimens around US 6,884,793?
The provided input is limited to US 6,884,793 claim language and does not include:
- patent family members,
- assignees,
- publication numbers,
- related continuations/divisionals,
- FDA product linkages (Orange Book listing, application number, NDC),
- or other patents in the Orange Book for the relevant EV + DNG contraceptive.
Because of that, a complete landscape map (other patents, their claim scope, expiration dates, and litigation posture) cannot be produced from the information given.
Key takeaways
- US 6,884,793 protects a 28-day multiphase oral contraception regimen with EV-only start and EV-only end (lower EV dose), plus a middle EV + DNG segment split into two DNG dose levels.
- Literal infringement depends on matching:
- stage sequence and exact day counts (claim 1: 2/5/17/2/2; claim 3: 3/4/16/2/3),
- EV dose relationship (stage 3 EV is “same” but smaller than stage 1 EV),
- DNG subgroup ratio (1.5x to 3x between second-group and first-group within stage 2),
- and, for dependent claims, numeric constraints (EV 3–4 mg/day, DNG 1 mg/day in claim 5).
- The tightness of the day-count and ratio limitations makes the patent most vulnerable to design-arounds that alter pack programming or subgroup ratio.
FAQs
1) What regimen elements must match to infringe claim 1 of US 6,884,793?
EV-only first stage (2 days), EV-only third stage (2 days) with lower EV than stage 1, second stage split into 5 days (EV + lower DNG) and 17 days (EV + higher DNG) with DNG ratio 1.5–3x, and a 2-day placebo stage.
2) How does claim 3 differ from claim 1 in schedule structure?
Claim 3 changes stage 1 to 3 EV-only days, changes the second-stage subgroup split to 4 lower-DNG days + 16 higher-DNG days, and increases placebo days to 3.
3) Does the patent require the same EV dose throughout the entire second stage?
Yes. Claim 1 and claim 3 require “respective amounts of estradiol valerate in each daily dosage portion” in the second stage to be equal.
4) What does the “minimum amounts necessary for effective contraceptive activity” language constrain?
It limits the DNG amount in the first group of the second stage to dosing levels deemed minimally effective for contraceptive activity, rather than a free numeric selection.
5) If an accused product keeps the EV+DNG molecules but changes the day allocation, does it avoid infringement?
Based on claim text, changing the subgroup day counts (5/17 vs 4/16, and 2 vs 3 placebo days) can avoid literal infringement because those counts are recited as claim elements.
References
(No sources cited because the provided input includes only the claim text for US 6,884,793 and does not include any bibliographic details to support citation.)
